A recent jury verdict in a talc-related lawsuit against Johnson & Johnson has once again placed product liability, corporate accountability, and litigation risk under intense scrutiny. The decision, one of many in a long-running series of cases, underscores the financial and reputational challenges facing multinational consumer health companies amid claims tied to legacy products. While Johnson & Johnson continues to contest the scientific basis of the allegations, the ruling highlights broader concerns around risk disclosure, legal strategy, and balance-sheet exposure.